Table 3.

List of ligands and their in silico binding affinity to the cV1bR.

SL. No.	Ligand	ΔGbinding (kcal/mol)
1	Manning compound; (d(CH2)51(Me)2,Arg8)-Vasopressin	−9.2
2	3rd Compound of Table 10 in Fabio et al., 2010; Sanofi compound derivative by Taisho Pharm. Co.	−8.9
3	Compound 2h of Table 9 in Fabio et al., 2010; l-(oxo-4H-quinazolin-3-yl) acetamide derivative	−8.8
4	4th Compound of Table 10 in Fabio et al., 2010; Sanofi compound derivative by Taisho Pharm. Co.	−8.3
5	Compound 12j in Napier et al., 2011; 2-(4-oxo-2-aryl-quinazolin-3(4H)-yl) acetamide derivative	−8.3
6	SR-49059((2S)-l-[(2R,3S)-5-chloro-3-(2-chlorophenyl)-l-3,4-dimethoxyphenyl)sulfonyl-3-hydroxy-2H-indole-2-carbonyl]pyrrolidine-2-carboxamide)	−7.9
7	SSR-149415;((2S,4R)-l-[5-Chloro-l-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2- oxo-2,3-dihydro-lH-indol-3-yll-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide)	−7.9
8	Compound 30P of Table 3 in Scott et al., 2009; Tetrahydroquinoline sulfonamide derivative	−7.6
9	L-368,899; l-((7,7-Dimethyl-2(S)-(2(S)-amino-4(methylsulfonyl)butyramido) bicyclo[2,2,l] heptan-l(S)-yl)methylsulfonyl)-4-(2-methylphenyl)piperazine hydrochloride	−7.3
10	[Arg8]-Vasotocin	−7.3

^¶The more negative score represent the higher binding affinity